<span id="midArticle_start"/> The Swiss blue-chip SMI index was seen opening 0.1 percent higher at 9,249 points onMonday, according to pre-market indications by bank Julius Baer.
<span id="midArticle_0"/>The following are some of the main factors expected toaffect Swiss stocks on Monday:
<span id="midArticle_1"/>
<span id="midArticle_2"/>COMPANY STATEMENTS
<span id="midArticle_3"/>* Holcim said it is launching the public exchangeoffer for all Lafarge shares at an exchange ratio of 9Holcim shares for 10 Lafarge shares, following the clearancefrom the Autorite des Marches Financiers on May 28.
<span id="midArticle_4"/>* Novartis said data from the Phase III COMBI-dstudy shows a significant survival benefit for patients withBRAF V600E/K mutation-positive metastatic melanoma when treatedwith the combination of Tafinlar and Mekinist, compared toTafinlar monotherapy alone.
<span id="midArticle_5"/>* Roche said its investigational cancerimmunotherapy atezolizumab was shown to shrink tumours intwo-thirds of people with the most common type of lung cancerwhen combined with chemotherapy, in a Phase 1b study.
<span id="midArticle_6"/>* Roche said it will present updated data from aPhase Ia study in people with previously treated, metastaticurothelial bladder cancer showing investigational cancerimmunotherapy atezolizumab shrank tumours in 50 percent ofpeople whose cancer expressed high levels of programmed deathligand-1, or PD-L1.
<span id="midArticle_7"/>* Roche said its Perjeta regimen helped people withHER2-positive early breast cancer live longer without theirdisease returning or getting worse compared to Herceptin andchemotherapy.
<span id="midArticle_8"/> <span class="first-article-divide"/>* Roche said phase III study shows Avastin drugimproves survival in patients with mesothelioma, a type ofthoracic cancer, which will be presented at an annual meeting ofthe American Society of Clinical Oncology (ASCO).
<span id="midArticle_9"/>* Roche said data shows an investigationalcombination of cobimetinib and zelboraf helps people withadvanced melanoma live for a year without their diseaseworsening.
<span id="midArticle_10"/>* Roche said results from the Phase III GADOLINstudy show that Gazyva, or Gazyvaro, plus bendamustine followedby Gazyva/Gazyvaro alone provided significant benefit for peoplewith indolent non-Hodgkin's lymphoma that is refractory toMabThera-, or Rituxan, based treatment.
<span id="midArticle_11"/>* Roche said phase III results from a collaborativegroup study showed that patients with malignant pleuralmesothelioma, a rare type of cancer that affects the lining ofthe lungs, lived significantly longer when treated withAvastin in combination with standard, compared to standardtherapy alone.
<span id="midArticle_12"/> <span class="second-article-divide"/>* Zehnder Group AG said it will cut 10 percent ofits workforce, 3,185 people at year-end, due to the strong Swissfranc after a central bank decision to abandon a cap on thecurrency, as well as shut sites in Rustington, UK and Vedelago,Italy while strategic options for a production facility inChalons-en-Champagne, France are currently under review. Theimplementation of the measures is forecast to result in aone-off expense of approximately 20 million euros ($21.92million).
<span id="midArticle_13"/>* EFG International AG said it has hired CreditSuisse banker Philippe Bruyere to be Head of PrivateBanking Geneva. Bruyere will report to Adrian Kyriazi, ChiefExecutive of Continental Europe and head of private bankingSwitzerland.
<span id="midArticle_14"/>* Swiss Prime Site said it named Markus Meier asnew Chief Financial Officer effective immediately. Meier iscurrently in the position on an interim basis following thedeparture of the previous CFO last year.
<span id="midArticle_15"/>
<span id="midArticle_0"/> <span class="third-article-divide"/>ECONOMY
<span id="midArticle_1"/>Weekly sight deposits due at 0700 GMT
<span id="midArticle_2"/>Manufacturing PMI data for May due at 0730 GMT
<span id="midArticle_3"/>
<span id="midArticle_4"/>The Swiss franc is too strong but should weaken, the SwissNational Bank's chairman has told a Swiss newspaper, adding thatthe bank was ready to intervene in foreign exchange markets ifnecessary, to influence the currency.
<span id="midArticle_5"/>For more, click on
<span id="midArticle_6"/>($1 = 0.9124 euros) (Reporting by Zurich newsroom)
<span id="midArticle_7"/>
<span id="midArticle_0"/>The following are some of the main factors expected toaffect Swiss stocks on Monday:
<span id="midArticle_1"/>
<span id="midArticle_2"/>COMPANY STATEMENTS
<span id="midArticle_3"/>* Holcim said it is launching the public exchangeoffer for all Lafarge shares at an exchange ratio of 9Holcim shares for 10 Lafarge shares, following the clearancefrom the Autorite des Marches Financiers on May 28.
<span id="midArticle_4"/>* Novartis said data from the Phase III COMBI-dstudy shows a significant survival benefit for patients withBRAF V600E/K mutation-positive metastatic melanoma when treatedwith the combination of Tafinlar and Mekinist, compared toTafinlar monotherapy alone.
<span id="midArticle_5"/>* Roche said its investigational cancerimmunotherapy atezolizumab was shown to shrink tumours intwo-thirds of people with the most common type of lung cancerwhen combined with chemotherapy, in a Phase 1b study.
<span id="midArticle_6"/>* Roche said it will present updated data from aPhase Ia study in people with previously treated, metastaticurothelial bladder cancer showing investigational cancerimmunotherapy atezolizumab shrank tumours in 50 percent ofpeople whose cancer expressed high levels of programmed deathligand-1, or PD-L1.
<span id="midArticle_7"/>* Roche said its Perjeta regimen helped people withHER2-positive early breast cancer live longer without theirdisease returning or getting worse compared to Herceptin andchemotherapy.
<span id="midArticle_8"/> <span class="first-article-divide"/>* Roche said phase III study shows Avastin drugimproves survival in patients with mesothelioma, a type ofthoracic cancer, which will be presented at an annual meeting ofthe American Society of Clinical Oncology (ASCO).
<span id="midArticle_9"/>* Roche said data shows an investigationalcombination of cobimetinib and zelboraf helps people withadvanced melanoma live for a year without their diseaseworsening.
<span id="midArticle_10"/>* Roche said results from the Phase III GADOLINstudy show that Gazyva, or Gazyvaro, plus bendamustine followedby Gazyva/Gazyvaro alone provided significant benefit for peoplewith indolent non-Hodgkin's lymphoma that is refractory toMabThera-, or Rituxan, based treatment.
<span id="midArticle_11"/>* Roche said phase III results from a collaborativegroup study showed that patients with malignant pleuralmesothelioma, a rare type of cancer that affects the lining ofthe lungs, lived significantly longer when treated withAvastin in combination with standard, compared to standardtherapy alone.
<span id="midArticle_12"/> <span class="second-article-divide"/>* Zehnder Group AG said it will cut 10 percent ofits workforce, 3,185 people at year-end, due to the strong Swissfranc after a central bank decision to abandon a cap on thecurrency, as well as shut sites in Rustington, UK and Vedelago,Italy while strategic options for a production facility inChalons-en-Champagne, France are currently under review. Theimplementation of the measures is forecast to result in aone-off expense of approximately 20 million euros ($21.92million).
<span id="midArticle_13"/>* EFG International AG said it has hired CreditSuisse banker Philippe Bruyere to be Head of PrivateBanking Geneva. Bruyere will report to Adrian Kyriazi, ChiefExecutive of Continental Europe and head of private bankingSwitzerland.
<span id="midArticle_14"/>* Swiss Prime Site said it named Markus Meier asnew Chief Financial Officer effective immediately. Meier iscurrently in the position on an interim basis following thedeparture of the previous CFO last year.
<span id="midArticle_15"/>
<span id="midArticle_0"/> <span class="third-article-divide"/>ECONOMY
<span id="midArticle_1"/>Weekly sight deposits due at 0700 GMT
<span id="midArticle_2"/>Manufacturing PMI data for May due at 0730 GMT
<span id="midArticle_3"/>
<span id="midArticle_4"/>The Swiss franc is too strong but should weaken, the SwissNational Bank's chairman has told a Swiss newspaper, adding thatthe bank was ready to intervene in foreign exchange markets ifnecessary, to influence the currency.
<span id="midArticle_5"/>For more, click on
<span id="midArticle_6"/>($1 = 0.9124 euros) (Reporting by Zurich newsroom)
<span id="midArticle_7"/>
via Smart Health Shop Forum http://ift.tt/1GQErsu
No comments:
Post a Comment